At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 9, 2026 at 07:30 ET
CervoMed reported a Q3 2026 net loss of $5.9M, narrower than the $7.7M loss in Q3 2025, driven by lower R&D spending after the completion of its Phase 2b RewinD-LB trial. The company had $19.6M in cash, expected to fund operations through Q3 2027. Key upcoming catalysts include 24-week biomarker data from the nfvPPA Phase 2a trial at CTAD 2026 and topline data from the RESTORE stroke trial by year-end 2026.
- Net loss of $5.9M for Q3 2026 vs $7.7M in Q3 2025
- Cash and marketable securities of $19.6M as of Sep 30, 2026, expected to fund operations through Q3 2027
- No grant revenue recognized in Q3 2026 vs $0.3M in Q3 2025, due to completion of RewinD-LB trial
- R&D expenses decreased to $3.7M from $6.0M year-over-year
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access